A Novel Bifunctional Fusion Protein, Vunakizumab-IL22, for Protection Against Pulmonary Immune Injury Caused by Influenza Virus
Influenza A virus an infection is normally related to acute lung harm, which is usually characterised by tracheal mucosal barrier harm and an interleukin 17A (IL-17A)-mediated inflammatory response in lung tissues. Though focusing on IL-17A has been confirmed to be … Read More